5PSQ-032 Effectiveness and safety in the use of sofosbubir/velpatasvir in the treatment of chronic hepatitis c virus infection

<h3>Background and Importance</h3> Hepatitis C virus (HCV) causes chronic infection in 55–85% of patients, increases the risk of liver cirrhosis to 15–30% in 20 years and is the main cause of hepatocellular carcinoma (70–80%) in Spain. <h3>Aim and Objectives</h3> To evaluate the effectiveness, safety and drug interaction profile of sofosbuvir/velpatasvir in patients with chronic HCV. <h3>Material and Methods</h3> This is an observational, retrospective study that included all HCV patients treated with sofosbuvir/velpatasvir from Januarya 2019 to July 2023 in a tertiary hospital. Variables: sex, age at baseline, viral load (VL) at baseline (VL0), HCV genotype, degree of fibrosis, co-infection with Human Immunodeficiency Virus (HIV), previous treatments, combination with ribavirin and potential drug interactions with concomitant treatment, VL at the end of treatment (VLend) and at 12 and 24 weeks after completion (VL12 and VL24), sustained viral response (SVR) was defined as undetectable VL12/VL24 (SVR12/SVR24) and adverse reactions (ARs) reported by patients. <h3>Results</h3> We included 80 patients, 70.0% (N=56) men, with a median age of 53.8 years (IQR: 49,0–58.8). 10.0% (N=8) of patients have received interferon or interferon+ribavirin. 8.8% (N=7) had HIV co-infection. The degree of fibrosis recorded was F0: 18.8% (N=15), F1: 15.0% (N=12), F2: 7.5% (N=6), F3: 18.8% (N=15), F4: 40.0% (N=32). The most frequent genotype was type 1; 36.3% (N=29) 1A and 26.3% (N=21)1B; 2, 3, 4 and other genotypes the prevalence was 1.3% (N=1), 18.8% (N=15), 11.3% (N=9) and 6.3% (N=5), respectively. The association with ribavirin was used in 7.5% of patients (N=6). The median VL0 was 668482,5 (IQR: 6942, 0–2422213,5) IU/mL. 36,3% (N=29) of patients were identified with potential drug interactions: 58,6% (N=17) proton pump inhibitors, 13,8% (N=4) metamizole, 13,8% (N=4) statins, 10,3% (N=3) carvedilol, 6,9% (N=2) digoxin and 3,4 % (N=1) tenofovir and ranitidine. 37,5% (N=30) of patients reported AR, the most frequent were fatigue 46,7% (N=14), gastrointestinal disturbances 46,7% (N=14) and headache 33,3% (N=10). SVR12 was achieved in 96,7% of patients (N=58). Two patients did not achieve SVR12, one patient due to vomiting that compromised the treatment and another patient with genotype 4 and previous failure to interferon+ribavirin. All patients with SVR12 maintain SVR24. <h3>Conclusion and Relevance</h3> Sofosvubir/velpatasvir is an effective and safe therapy for the treatment of HCV infection. The potential drug-drug interactions of DAAs highlight the importance of pharmaceutical care in this group of patients. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest